Ação do ultra-som de baixa intensidade sobre ossos de ratas osteopênicas

Several studies have already shown the beneficial effects of low intensity pulsed ultrasound on osteogenesis in fracture cases. However, few reports have related the ultrasound action in bone with some injury but without fracture. Thus, we induced a rat osteopenia model by ovariectomy and the proximal third of rat femur was stimulated by ultrasound (200mus burst of 1.5 MHz sine waves repeated at 1.0 kHz, 30mW/cm², SATA) for 20 min/day, during 20 days. After the treatment period, the body weight was significantly higher in the non-treated group than the treated one. No significant difference in bone mineral content was detected among the groups (p > 0.05). Also, no significant difference was noted in the mechanical properties of the femoral diaphysis. However, histologic investigations showed that the treated femur presented less microarchitectural deterioration than the non-treated group. Moreover, it was demonstrated that the treated group did show recent bone formation which was not there in the non-treated group. These results suggest that the low intensity ultrasound can interfere in a positive way on osteoporosis.Neste estudo, nós analisamos a ação do ultra-som pulsado de baixa intensidade (30mW/cm², freqüência de repetição de 1Khz e ciclo de trabalho de 20%) durante 20 dias consecutivos, por 20 minutos diários, como método não invasivo, em modelo de ratas osteopênicas. A estimulação ultra-sônica foi realizada na região proximal dos fêmures, bilateralmente. Apesar dos resultados quantitativos do conteúdo mineral ósseo (cálcio e fósforo) não terem demonstrado diferenças significativas (p >0,05) entre os grupos tratado e não tratado, as investigações histológicas mostraram que o fêmur tratado apresentou uma menor deterioração microarquitetural que o grupo não tratado, além da ocorrência de neoformação óssea, a qual não foi observada no grupo não tratado. Os resultados sugerem que o ultra-som pulsado de baixa intensidade pode interferir positivamente sobre a osteoporose.172

Disuse ostoporosis: its relationship to spine cord injuried patient rehabilitation

Osteoporosis is a very much frequent metabolic disease among spine cord injuried patients. Their rehabilitation can be jeopardized by this disease, due to the possibility of fractures of the osteoporotic bones. Osteoporosis in spine injuried patients is related to the disuse caused by palsy, which leads to less mechanic stress over the bones, and as a consequence, less bone formation stimulation, with a not proportional bone absorption, which makes bone fragile. Thus, alternative non pharmacological treatments based on bone biomechanics principles are under study, which include an analysis of weight bearing caused by neuromuscular electrical stimulation (NMES) and low intensity ultra sound. This article is proposed to explain the importance of mechanic stimulation over the bones and the consequences of its absence, with an emphasis on spine cord injuried patients, and to discuss alternative treatments already studied.A osteoporose é uma doença óssea metabólica muito freqüente em pacientes que sofreram lesão medular. Seu aparecimento pode prejudicar os tratamentos de reabilitação destes pacientes, devido à possibilidade de ocorrência de fraturas em seus ossos osteoporóticos. A osteoporose em lesados medulares está relacionada com o desuso causado pela paralisia, a qual provoca diminuição da tensão mecânica sobre os ossos, e consequentemente, diminuição do estímulo à formação de osso com aumento desproporcional da reabsorção óssea, tornando o osso mais frágil. Assim, tratamentos alternativos não farmacológicos, baseados no princípio biomecânico do osso, estão sendo estudados, os quais incluem a análise da sustentação de peso causada pela estimulação elétrica neuro-muscular (EENM), e o ultra-som de baixa intensidade. Este artigo propõe explicar a importância do estímulo mecânico sobre os ossos e as conseqüências de sua ausência, com ênfase nos pacientes lesados medulares. Além de mostrar tratamentos alternativos que têm sido estudados.344

Labor Induction with Misoprostol: comparison of two Dose regimens

-Objetivo: comparar a eficácia e segurança entre duas doses de misoprostol administradas por via vaginal para amadurecimento cervical e indução do parto. Pacientes e Métodos: sessenta e uma pacientes com indicação médica para indução do parto e colo desfavorável foram incluídas neste estudo. Vinte e oito pacientes receberam 25 µg e trinta e três 50 µg de misoprostol, a intervalos de 4 horas, até um período máximo de 24 horas. Resultados: a rotura prematura de membranas, gestação prolongada e doença hipertensiva específica da gestação foram as principais indicações para a indução do parto. O intervalo de tempo, em minutos, entre inserção do misoprostol até o parto vaginal foi similar nos grupos de 25 µg (416,3 ± 148,1) e 50 µg (425 ± 135,9). A porcentagem de parto vaginal foi de 82,2% e 81,9% nos grupos de 25 e 50 µg, respectivamente. Não houve diferença significativa entre os grupos no que se refere a complicações maternas e fetais. Conclusões: a administração de misoprostol por via vaginal mostrou-se um método eficiente e seguro para o amadurecimento cervical e indução do parto. A dose de 25 µg mostrou ter eficácia e segurança comparável à de 50 µg

Genetic variation in PFKFB3 impairs antifungal immunometabolic responses and predisposes to Invasive Pulmonary Aspergillosis

Copyright © 2021 Gonçalves et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.Activation of immune cells in response to fungal infection involves the reprogramming of their cellular metabolism to support antimicrobial effector functions. Although metabolic pathways such as glycolysis are known to represent critical regulatory nodes in antifungal immunity, it remains undetermined whether these are differentially regulated at the interindividual level. In this study, we identify a key role for 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3) in the immunometabolic responses to Aspergillus fumigatus. A genetic association study performed in 439 recipients of allogeneic hematopoietic stem cell transplantation (HSCT) and corresponding donors revealed that the donor, but not recipient, rs646564 variant in the PFKFB3 gene increased the risk of invasive pulmonary aspergillosis (IPA) after transplantation. The risk genotype impaired the expression of PFKFB3 by human macrophages in response to fungal infection, which was correlated with a defective activation of glycolysis and the ensuing antifungal effector functions. In patients with IPA, the risk genotype was associated with lower concentrations of cytokines in the bronchoalveolar lavage fluid samples. Collectively, these findings demonstrate the important contribution of genetic variation in PFKFB3 to the risk of IPA in patients undergoing HSCT and support its inclusion in prognostic tools to predict the risk of fungal infection in this clinical setting. IMPORTANCE The fungal pathogen Aspergillus fumigatus can cause severe and life-threatening forms of infection in immunocompromised patients. Activation of glycolysis is essential for innate immune cells to mount effective antifungal responses. In this study, we report the contribution of genetic variation in the key glycolytic activator 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3) to the risk of invasive pulmonary aspergillosis (IPA) after allogeneic hematopoietic stem cell transplantation. The PFKFB3 genotype associated with increased risk of infection was correlated with an impairment of the antifungal effector functions of macrophages in vitro and in patients with IPA. This work highlights the clinical relevance of genetic variation in PFKFB3 to the risk of IPA and supports its integration in risk stratification and preemptive measures for patients at high risk of IPA.This work was supported by the Fundação para a Ciência e Tecnologia (FCT) (PTDC/SAU-SER/29635/2017, PTDC/MED-GEN/28778/2017, UIDB/50026/2020, and UIDP/50026/2020), the Northern Portugal Regional Operational Program (NORTE 2020), under the Portugal 2020 Partnership Agreement, through the European Regional Development Fund (ERDF) (NORTE-01-0145-FEDER-000039), the Institut Mérieux (Mérieux Research Grant 2017), the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Research Grant 2017), the European Union’s Horizon 2020 research and innovation program under grant agreement no. 847507, and the “la Caixa” Foundation (ID 100010434) and FCT under the agreement LCF/PR/HR17/52190003. Individual support was provided by FCT (SFRH/BD/136814/2018 to S.M.G., PD/BD/137680/2018 to D.A., CEECIND/04058/2018 to C.C., and CEECIND/03628/2017 to A.C.). M.G.N. was supported by an ERC Advanced Grant and a Spinoza Grant of the Netherlands Organization for Scientific Research.info:eu-repo/semantics/publishedVersio

Phagosomal removal of fungal melanin reprograms macrophage metabolism to promote antifungal immunity

Acknowledgements This work was supported by the Northern Portugal Regional Operational Programme (NORTE 2020), under the Portugal 2020 Partnership Agreement, through the European Regional Development Fund (FEDER) (NORTE-01- 0145-FEDER-000013), the Fundação para a Ciência e Tecnologia (FCT) (SFRH/BD/136814/2018 to S.M.G., SFRH/BD/141127/2018 to C.D.O., PD/BD/137680/2018 to D.A., IF/00474/2014 to N.S.O., IF/01390/2014 to E.T., IF/00959/2014 to S.C., IF/00021/2014 to R.S., PTDC/SAU-SER/29635/2017 and CEECIND/04601/2017 to C.C., and CEECIND/03628/2017 to A.C.), the Institut Mérieux (Mérieux Research Grant 2017 to C.C.), and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Research Grant 2017 to A.C.). M.G.N. was supported by a Spinoza grant of the Netherlands Organization for Scientific Research. A.A.B. was supported by the Deutsche Forschungsgemeinschaft Collaborative Research Center/Transregio TR124 FungiNet (project A1). G.D.B. was funded by the Wellcome Trust (102705), the MRC Centre for Medical Mycology and the University of Aberdeen (MR/N006364/1).Peer reviewedPublisher PD

O 6º objetivo da agenda dos ODS da ONU: Debates sobre água segura y saneamento básico universalizado.

El proyecto de Trabajo Comunal Universitario (TCU) No. 540: Procesos pedagógicos y didácticos para la enseñanza de los derechos humanos y la convivencia pacífica, coordinado por la Dra. Marcela Moreno Buján, con la cooperación académica del proyecto de extensión docente Grupo de Pesquisa Derecho y Sustentabilidad (GPDS), coordinado por el Dr. Carlos Peralta Montero, han unido esfuerzos para organizar y publicar la Colección “Comunidad Académica y COVID 19”. Esta colección, conformada por tres volúmenes, forma parte de la sistematización de experiencias relacionadas con las temáticas abordadas por el TCU No. 540 y el GPDS. Este volumen está compuesto por doce capítulos, desarrollados por veintiocho académicos costarricenses, brasileños y colombianos donde se reflexiona de manera interdisciplinaria sobre el sexto objetivo de la agenda de los Objetivos de Desarrollo Sostenible (ODS) de la ONU en el contexto de pandemia actual.UCR::Vicerrectoría de Acción Social::Trabajo Comunal Universitario (TCU

Pesca do apaiari, Astronotus ocellatus (Agassiz, 1831), e perfil socioeconômico dos pescadores artesanais de uma região da Amazônia brasileira

The artisanal fishery is an important economic and subsistence activity among traditional populations in the Amazon Region. Therefore, the aim of this study was to characterize the fishery of apaiari, Astronotus ocellatus (Agassiz, 1831), and to present a socioeconomic profile of artisanal fishermen in the region lakes of Pracuúba, Amapá, Brazil. From May to August 2011 interviews were conducted using standardized forms with fishermen selected by "snowball" method and aged above 18 years old. A total of 68 fishing workers were interviewed, of which 55 were men and 13 women. It was possible to observe that fishing workers have a wide knowledge of fishery in the Region, including apaiari fishery, and that social and economic lives of the Pracuúba population depend totally of the artisanal fishery

SARS-CoV-2 introductions and early dynamics of the epidemic in Portugal

Genomic surveillance of SARS-CoV-2 in Portugal was rapidly implemented by the National Institute of Health in the early stages of the COVID-19 epidemic, in collaboration with more than 50 laboratories distributed nationwide. Methods By applying recent phylodynamic models that allow integration of individual-based travel history, we reconstructed and characterized the spatio-temporal dynamics of SARSCoV-2 introductions and early dissemination in Portugal. Results We detected at least 277 independent SARS-CoV-2 introductions, mostly from European countries (namely the United Kingdom, Spain, France, Italy, and Switzerland), which were consistent with the countries with the highest connectivity with Portugal. Although most introductions were estimated to have occurred during early March 2020, it is likely that SARS-CoV-2 was silently circulating in Portugal throughout February, before the first cases were confirmed. Conclusions Here we conclude that the earlier implementation of measures could have minimized the number of introductions and subsequent virus expansion in Portugal. This study lays the foundation for genomic epidemiology of SARS-CoV-2 in Portugal, and highlights the need for systematic and geographically-representative genomic surveillance.We gratefully acknowledge to Sara Hill and Nuno Faria (University of Oxford) and Joshua Quick and Nick Loman (University of Birmingham) for kindly providing us with the initial sets of Artic Network primers for NGS; Rafael Mamede (MRamirez team, IMM, Lisbon) for developing and sharing a bioinformatics script for sequence curation (https://github.com/rfm-targa/BioinfUtils); Philippe Lemey (KU Leuven) for providing guidance on the implementation of the phylodynamic models; Joshua L. Cherry (National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health) for providing guidance with the subsampling strategies; and all authors, originating and submitting laboratories who have contributed genome data on GISAID (https://www.gisaid.org/) on which part of this research is based. The opinions expressed in this article are those of the authors and do not reflect the view of the National Institutes of Health, the Department of Health and Human Services, or the United States government. This study is co-funded by Fundação para a Ciência e Tecnologia and Agência de Investigação Clínica e Inovação Biomédica (234_596874175) on behalf of the Research 4 COVID-19 call. Some infrastructural resources used in this study come from the GenomePT project (POCI-01-0145-FEDER-022184), supported by COMPETE 2020 - Operational Programme for Competitiveness and Internationalisation (POCI), Lisboa Portugal Regional Operational Programme (Lisboa2020), Algarve Portugal Regional Operational Programme (CRESC Algarve2020), under the PORTUGAL 2020 Partnership Agreement, through the European Regional Development Fund (ERDF), and by Fundação para a Ciência e a Tecnologia (FCT).info:eu-repo/semantics/publishedVersio

Design and baseline characteristics of the finerenone in reducing cardiovascular mortality and morbidity in diabetic kidney disease trial

Background: Among people with diabetes, those with kidney disease have exceptionally high rates of cardiovascular (CV) morbidity and mortality and progression of their underlying kidney disease. Finerenone is a novel, nonsteroidal, selective mineralocorticoid receptor antagonist that has shown to reduce albuminuria in type 2 diabetes (T2D) patients with chronic kidney disease (CKD) while revealing only a low risk of hyperkalemia. However, the effect of finerenone on CV and renal outcomes has not yet been investigated in long-term trials. Patients and Methods: The Finerenone in Reducing CV Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD) trial aims to assess the efficacy and safety of finerenone compared to placebo at reducing clinically important CV and renal outcomes in T2D patients with CKD. FIGARO-DKD is a randomized, double-blind, placebo-controlled, parallel-group, event-driven trial running in 47 countries with an expected duration of approximately 6 years. FIGARO-DKD randomized 7,437 patients with an estimated glomerular filtration rate >= 25 mL/min/1.73 m(2) and albuminuria (urinary albumin-to-creatinine ratio >= 30 to <= 5,000 mg/g). The study has at least 90% power to detect a 20% reduction in the risk of the primary outcome (overall two-sided significance level alpha = 0.05), the composite of time to first occurrence of CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure. Conclusions: FIGARO-DKD will determine whether an optimally treated cohort of T2D patients with CKD at high risk of CV and renal events will experience cardiorenal benefits with the addition of finerenone to their treatment regimen. Trial Registration: EudraCT number: 2015-000950-39; ClinicalTrials.gov identifier: NCT02545049